Literature DB >> 27467909

Ovarian cancer chemokines may not be a significant barrier during whole tumor antigen dendritic-cell vaccine and adoptive T-cell immunotherapy.

Emese Zsiros1, Denarda Dangaj2, Carl H June3, Lana E Kandalaft4, George Coukos4.   

Abstract

Tumor barriers preventing T-cell homing and engraftment should be neutralized during cancer immunotherapy. We recently discovered that ovarian cancer expresses quasi-universal chemokines that can support T-cell homing. Furthermore, T cells elicited by whole tumor antigen dendritic-cell vaccines express cognate chemokine receptors which are upregulated by CD3/CD28 costimulation.

Entities:  

Keywords:  Adoptive T cell therapy; chemokines; immunotherapy; ovarian cancer

Year:  2015        PMID： 27467909      PMCID： PMC4910715          DOI： 10.1080/2162402X.2015.1062210

Source DB:  PubMed          Journal:  Oncoimmunology        ISSN： 2162-4011            Impact factor:   8.110


  10 in total

1.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.

Authors:  Eiichi Sato; Sara H Olson; Jiyoung Ahn; Brian Bundy; Hiroyoshi Nishikawa; Feng Qian; Achim A Jungbluth; Denise Frosina; Sacha Gnjatic; Christine Ambrosone; James Kepner; Tosin Odunsi; Gerd Ritter; Shashikant Lele; Yao-Tseng Chen; Haruo Ohtani; Lloyd J Old; Kunle Odunsi
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-12       Impact factor: 11.205

2.  A dendritic cell vaccine pulsed with autologous hypochlorous acid-oxidized ovarian cancer lysate primes effective broad antitumor immunity: from bench to bedside.

Authors:  Cheryl Lai-Lai Chiang; Lana E Kandalaft; Janos Tanyi; Andrea R Hagemann; Gregory T Motz; Nikolaos Svoronos; Kathleen Montone; Gina M Mantia-Smaldone; Lori Smith; Harvey L Nisenbaum; Bruce L Levine; Michael Kalos; Brian J Czerniecki; Drew A Torigian; Daniel J Powell; Rosemarie Mick; George Coukos
Journal:  Clin Cancer Res       Date:  2013-07-09       Impact factor: 12.531

Review 3.  Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance.

Authors:  Lana E Kandalaft; Gregory T Motz; Jaikumar Duraiswamy; George Coukos
Journal:  Cancer Metastasis Rev       Date:  2011-03       Impact factor: 9.264

4.  The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28-Costimulated T Cells Prepared for Adoptive Therapy.

Authors:  Emese Zsiros; Priyanka Duttagupta; Denarda Dangaj; Hongzhe Li; Renee Frank; Thomas Garrabrant; Ian S Hagemann; Bruce L Levine; Carl H June; Lin Zhang; Ena Wang; Francesco M Marincola; Davide Bedognetti; Daniel J Powell; Janos Tanyi; Michael D Feldman; Lana E Kandalaft; George Coukos
Journal:  Clin Cancer Res       Date:  2015-02-23       Impact factor: 12.531

Review 5.  Chemokines in cancer.

Authors:  Melvyn T Chow; Andrew D Luster
Journal:  Cancer Immunol Res       Date:  2014-12       Impact factor: 11.151

6.  Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

Authors:  Lin Zhang; Jose R Conejo-Garcia; Dionyssios Katsaros; Phyllis A Gimotty; Marco Massobrio; Giorgia Regnani; Antonis Makrigiannakis; Heidi Gray; Katia Schlienger; Michael N Liebman; Stephen C Rubin; George Coukos
Journal:  N Engl J Med       Date:  2003-01-16       Impact factor: 91.245

7.  Day-4 myeloid dendritic cells pulsed with whole tumor lysate are highly immunogenic and elicit potent anti-tumor responses.

Authors:  Cheryl Lai-Lai Chiang; Andrea R Hagemann; Rachel Leskowitz; Rosemarie Mick; Thomas Garrabrant; Brian J Czerniecki; Lana E Kandalaft; Daniel J Powell; George Coukos
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

8.  Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors.

Authors:  Gregory T Motz; Stephen P Santoro; Li-Ping Wang; Tom Garrabrant; Ricardo R Lastra; Ian S Hagemann; Priti Lal; Michael D Feldman; Fabian Benencia; George Coukos
Journal:  Nat Med       Date:  2014-05-04       Impact factor: 53.440

9.  Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer.

Authors:  Lana E Kandalaft; Daniel J Powell; Cheryl L Chiang; Janos Tanyi; Sarah Kim; Marnix Bosch; Kathy Montone; Rosemarie Mick; Bruce L Levine; Drew A Torigian; Carl H June; George Coukos
Journal:  Oncoimmunology       Date:  2013-01-01       Impact factor: 8.110

10.  A Phase I vaccine trial using dendritic cells pulsed with autologous oxidized lysate for recurrent ovarian cancer.

Authors:  Lana E Kandalaft; Cheryl L Chiang; Janos Tanyi; Greg Motz; Klara Balint; Rosemarie Mick; George Coukos
Journal:  J Transl Med       Date:  2013-06-18       Impact factor: 5.531
  10 in total
  3 in total

1.  Driver pattern identification over the gene co-expression of drug response in ovarian cancer by integrating high throughput genomics data.

Authors:  Xinguo Lu; Jibo Lu; Bo Liao; Xing Li; Xin Qian; Keqin Li
Journal:  Sci Rep       Date:  2017-11-23       Impact factor: 4.379

2.  Transimmunization restores immune surveillance and prevents recurrence in a syngeneic mouse model of ovarian cancer.

Authors:  Ayesha B Alvero; Douglas Hanlon; Mary Pitruzzello; Renata Filler; Eve Robinson; Olga Sobolev; Roslyn Tedja; Alessandra Ventura; Marcus Bosenberg; Patrick Han; Richard L Edelson; Gil Mor
Journal:  Oncoimmunology       Date:  2020-05-13       Impact factor: 8.110

Review 3.  Immunotherapy Advances for Epithelial Ovarian Cancer.

Authors:  Erin G Hartnett; Julia Knight; Mackenzy Radolec; Ronald J Buckanovich; Robert P Edwards; Anda M Vlad
Journal:  Cancers (Basel)       Date:  2020-12-11       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.